
Agios Pharmaceuticals, Inc.: shareholders and insiders
Price
$27.60
November 20, 2026Market cap $1.6B
What Ploutos Investor adds for Agios Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 15 fiscal years, from 2011
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Nov 21, 2025 to Oct 28, 2026, from their own Form 4 filings.
Bought on the market
–
nobody
Sold on the market
$4.8M
7 people
From Nov 21, 2025 to Nov 21, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan97%
- The rest3%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 21, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·no buys·sold $4.0M by 7 people
- 2025: no buys, sold $824.4K by 5 people
- 2026: no buys, sold $4.0M by 7 people
- Oct 26, 2026Sarah GheuensChief Medical OfficerKind10b5-1
- Oct 26, 2026Sarah GheuensChief Medical OfficerKind10b5-1
- Oct 22, 2026Sarah GheuensChief Medical OfficerKind10b5-1
- Oct 22, 2026Sarah GheuensChief Medical OfficerKind10b5-1
- Oct 21, 2026Sarah GheuensChief Medical OfficerKind10b5-1
- Oct 21, 2026Sarah GheuensChief Medical OfficerKind10b5-1
- Aug 4, 2026Sarah GheuensChief Medical OfficerKind10b5-1
- Jul 8, 2026Jay T. BackstromDirectorKind
- Jul 1, 2026Sarah GheuensChief Medical OfficerKind10b5-1
- Jul 1, 2026Sarah GheuensChief Medical OfficerKind10b5-1
- Jun 18, 2026Rahul D. BallalDirectorKind
- Jun 18, 2026Jeffrey D CapelloDirectorKind
- Jun 18, 2026Kaye I Foster-CheekDirectorKind
- Jun 18, 2026Jacqualyn A FouseDirectorKind
- Jun 18, 2026Maykin HoDirectorKind
- Jun 18, 2026Adams Catherine OwenDirectorKind
- Jun 18, 2026David ScaddenDirectorKind
- Jun 18, 2026Cynthia SmithDirectorKind
- Jun 13, 2026Adams Catherine OwenDirectorKind
- Jun 13, 2026Jeffrey D CapelloDirectorKind
- Apr 2, 2026Brian GoffChief Executive OfficerKind10b5-1
- Apr 2, 2026Brian GoffChief Executive OfficerKind10b5-1
- Apr 2, 2026Krishnan ViswanadhanChief Corp Dev & StrategyKind10b5-1
- Apr 2, 2026Tsveta MilanovaChief Commercial OfficerKind10b5-1
- Apr 2, 2026Cecilia JonesChief Financial OfficerKind10b5-1
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Oct 26, 2026 | Sarah GheuensChief Medical Officer | 10b5-1 | 7,866 | $25.01 | $196.7K | Form 4 |
| Oct 26, 2026 | Sarah GheuensChief Medical Officer | 10b5-1 | 7,866 | $37.69 | $296.5K | Form 4 |
| Oct 22, 2026 | Sarah GheuensChief Medical Officer | 10b5-1 | 500 | $25.01 | $12.5K | Form 4 |
| Oct 22, 2026 | Sarah GheuensChief Medical Officer | 10b5-1 | 500 | $37.52 | $18.8K | Form 4 |
| Oct 21, 2026 | Sarah GheuensChief Medical Officer | 10b5-1 | 1,489 | $25.01 | $37.2K | Form 4 |
| Oct 21, 2026 | Sarah GheuensChief Medical Officer | 10b5-1 | 1,489 | $37.53 | $55.9K | Form 4 |
| Aug 4, 2026 | Sarah GheuensChief Medical Officer | 10b5-1 | 30.0K | $30.48 | $914.4K | Form 4 |
| Jul 8, 2026 | Jay T. BackstromDirector | 1,447 | – | – | Form 4 | |
| Jul 1, 2026 | Sarah GheuensChief Medical Officer | 10b5-1 | 8,375 | – | – | Form 4 |
| Jul 1, 2026 | Sarah GheuensChief Medical Officer | 10b5-1 | 4,007 | $37.56 | $150.5K | Form 4 |
| Jun 18, 2026 | Rahul D. BallalDirector | 2,816 | – | – | Form 4 | |
| Jun 18, 2026 | Jeffrey D CapelloDirector | 2,816 | – | – | Form 4 | |
| Jun 18, 2026 | Kaye I Foster-CheekDirector | 2,816 | – | – | Form 4 | |
| Jun 18, 2026 | Jacqualyn A FouseDirector | 2,816 | – | – | Form 4 | |
| Jun 18, 2026 | Maykin HoDirector | 2,816 | – | – | Form 4 | |
| Jun 18, 2026 | Adams Catherine OwenDirector | 2,816 | – | – | Form 4 | |
| Jun 18, 2026 | David ScaddenDirector | 2,816 | – | – | Form 4 | |
| Jun 18, 2026 | Cynthia SmithDirector | 2,816 | – | – | Form 4 | |
| Jun 13, 2026 | Adams Catherine OwenDirector | 1,976 | – | – | Form 4 | |
| Jun 13, 2026 | Jeffrey D CapelloDirector | 1,976 | – | – | Form 4 | |
| Apr 2, 2026 | Brian GoffChief Executive Officer | 10b5-1 | 6,596 | $34.71 | $228.9K | Form 4 |
| Apr 2, 2026 | Brian GoffChief Executive Officer | 10b5-1 | 12.5K | $34.71 | $432.9K | Form 4 |
| Apr 2, 2026 | Krishnan ViswanadhanChief Corp Dev & Strategy | 10b5-1 | 2,959 | $34.71 | $102.7K | Form 4 |
| Apr 2, 2026 | Tsveta MilanovaChief Commercial Officer | 10b5-1 | 3,262 | $34.71 | $113.2K | Form 4 |
| Apr 2, 2026 | Cecilia JonesChief Financial Officer | 10b5-1 | 3,141 | $34.71 | $109.0K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 16, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by AGIO's officers and directors from 2013 up to November 20, 2025, 13 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 8 more, back to 2013
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- Farallon Capital Management, L.L.C.with 28 more personsShare of class9.90%
- BlackRock, Inc.Share of class7.80%
- State StreetShare of class5.30%
- Vanguard Capital ManagementShare of class5.27%
- D. E. Shaw & Co., L.P.with 1 more personShare of class5.10%
- Lynx1 Capital Management LPwith 1 more personShare of class5.10%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Farallon Capital Management, L.L.C.with 28 more persons | 9.90% | 5.92M | Aug 3, 20263 filings since Feb 4, 2025 | 13G/A | |
| BlackRock, Inc. | 7.80% | 4.51M | Jul 17, 2025 | 13G/A | |
| State Street | 5.30% | 3.11M | Feb 9, 2026 | 13G | |
| Vanguard Capital Management | 5.27% | 3.09M | Apr 29, 2026 | 13G | |
| D. E. Shaw & Co., L.P.with 1 more person | 5.10% | 3.03M | Jul 2, 2026 | 13G | |
| Lynx1 Capital Management LPwith 1 more person | 5.10% | 3.01M | May 6, 2026 | 13G |
Fell to 5% or less (5)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Glenview CapitalIn the quarter
- D.E. ShawIn the quarter+25%
- Point72 (Cohen)In the quarter
- Renaissance TechnologiesIn the quarter
- Citadel Advisors (Griffin)In the quarter+6.3%
- Millennium Mgmt (Englander)In the quarter
- AQR CapitalIn the quarter+9.1%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Glenview Capital | 459.8K | $15M | 0.27% | |
| D.E. Shaw | 3.89M | +25% | $129M | 0.08% |
| Point72 (Cohen) | – | – | 0.03% | |
| Renaissance Technologies | 505.6K | $17M | 0.02% | |
| Citadel Advisors (Griffin) | 778.6K | +6.3% | $26M | 0.01% |
| Millennium Mgmt (Englander) | 274.4K | $9.1M | 0.01% | |
| AQR Capital | 746.9K | +9.1% | $25M | 0.01% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 11.8% of its shares outstanding were held short, -1.7% since the report before.
- Shares held short
- 6.89M
- 11.8%
- Since the report before7.02M on Sep 30, 2026
- -1.7%
- 5.6
- 1.23M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 67%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 5.66M
- Nov 15, 2023: Shares held short 6.02M
- Nov 30, 2023: Shares held short 6.41M
- Dec 15, 2023: Shares held short 6.87M
- Dec 29, 2023: Shares held short 7.10M
- Jan 12, 2024: Shares held short 8.03M
- Jan 31, 2024: Shares held short 7.34M
- Feb 15, 2024: Shares held short 7.65M
- Feb 29, 2024: Shares held short 7.33M
- Mar 15, 2024: Shares held short 6.85M
- Mar 28, 2024: Shares held short 6.60M
- Apr 15, 2024: Shares held short 6.65M
- Apr 30, 2024: Shares held short 6.51M
- May 15, 2024: Shares held short 6.08M
- May 31, 2024: Shares held short 4.47M
- Jun 14, 2024: Shares held short 4.22M
- Jun 28, 2024: Shares held short 3.13M
- Jul 15, 2024: Shares held short 3.19M
- Jul 31, 2024: Shares held short 3.55M
- Aug 15, 2024: Shares held short 3.46M
- Aug 30, 2024: Shares held short 2.90M
- Sep 13, 2024: Shares held short 2.98M
- Sep 30, 2024: Shares held short 3.28M
- Oct 15, 2024: Shares held short 4.11M
- Oct 31, 2024: Shares held short 4.34M
- Nov 15, 2024: Shares held short 4.55M
- Nov 29, 2024: Shares held short 4.57M
- Dec 13, 2024: Shares held short 5.12M
- Dec 31, 2024: Shares held short 5.53M
- Jan 15, 2025: Shares held short 5.35M
- Jan 31, 2025: Shares held short 5.03M
- Feb 14, 2025: Shares held short 4.63M
- Feb 28, 2025: Shares held short 3.94M
- Mar 14, 2025: Shares held short 3.40M
- Mar 31, 2025: Shares held short 3.55M
- Apr 15, 2025: Shares held short 3.48M
- Apr 30, 2025: Shares held short 3.93M
- May 15, 2025: Shares held short 4.16M
- May 30, 2025: Shares held short 4.25M
- Jun 13, 2025: Shares held short 4.32M
- Jun 30, 2025: Shares held short 3.78M
- Jul 15, 2025: Shares held short 4.18M
- Jul 31, 2025: Shares held short 4.10M
- Aug 15, 2025: Shares held short 4.82M
- Aug 29, 2025: Shares held short 4.76M
- Sep 15, 2025: Shares held short 4.74M
- Sep 30, 2025: Shares held short 5.18M
- Oct 15, 2025: Shares held short 4.97M
- Oct 31, 2025: Shares held short 4.60M
- Nov 14, 2025: Shares held short 4.33M
- Nov 28, 2025: Shares held short 5.47M
- Dec 15, 2025: Shares held short 6.13M
- Dec 31, 2025: Shares held short 7.09M
- Jan 15, 2026: Shares held short 7.45M
- Jan 30, 2026: Shares held short 6.73M
- Feb 13, 2026: Shares held short 6.33M
- Feb 27, 2026: Shares held short 6.24M
- Mar 13, 2026: Shares held short 6.19M
- Mar 31, 2026: Shares held short 6.61M
- Apr 15, 2026: Shares held short 7.08M
- Apr 30, 2026: Shares held short 6.97M
- May 15, 2026: Shares held short 7.45M
- May 29, 2026: Shares held short 6.93M
- Jun 15, 2026: Shares held short 6.90M
- Jun 30, 2026: Shares held short 6.76M
- Jul 15, 2026: Shares held short 6.63M
- Jul 31, 2026: Shares held short 6.84M
- Aug 14, 2026: Shares held short 7.63M
- Aug 31, 2026: Shares held short 7.54M
- Sep 15, 2026: Shares held short 7.56M
- Sep 30, 2026: Shares held short 7.02M
- Oct 15, 2026: Shares held short 6.89M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading58.4% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 58.4% of the shares in the reported trades were short sales, against 59.8% in the 14 before.
- Last 14 sessionsNov 3, 2026 – Nov 20, 2026
- 58.4%
- The 14 beforeOct 14, 2026 – Nov 2, 2026
- 59.8%
- Change
- -1.4 pts
- Short sales a dayon average, of 277.0K shares
- 161.8K
- More than atof 3,674 US-listed companies, same days
- 78%
- Median of alleight in ten from 34.4% to 63.9%
- 50.5%
- Short sales
- Oct 14, 2026: Short sales 52.9%
- Oct 15, 2026: Short sales 75.4%
- Oct 16, 2026: Short sales 72.4%
- Oct 19, 2026: Short sales 71.9%
- Oct 20, 2026: Short sales 54.8%
- Oct 21, 2026: Short sales 63.8%
- Oct 22, 2026: Short sales 54.4%
- Oct 23, 2026: Short sales 64%
- Oct 26, 2026: Short sales 43%
- Oct 27, 2026: Short sales 37.8%
- Oct 28, 2026: Short sales 38.2%
- Oct 29, 2026: Short sales 42.5%
- Oct 30, 2026: Short sales 60.9%
- Nov 2, 2026: Short sales 76.2%
- Nov 3, 2026: Short sales 55.5%
- Nov 4, 2026: Short sales 58.8%
- Nov 5, 2026: Short sales 61.3%
- Nov 6, 2026: Short sales 53%
- Nov 9, 2026: Short sales 73.5%
- Nov 10, 2026: Short sales 51.2%
- Nov 11, 2026: Short sales 65.1%
- Nov 12, 2026: Short sales 62.5%
- Nov 13, 2026: Short sales 59.5%
- Nov 16, 2026: Short sales 59.8%
- Nov 17, 2026: Short sales 53.4%
- Nov 18, 2026: Short sales 55.3%
- Nov 19, 2026: Short sales 51.3%
- Nov 20, 2026: Short sales 43.7%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Brian GoffChief Executive OfficerDirectly184.5K
- Jacqualyn A FouseDirectorDirectly154.2K
- David P SchenkeinDirectorDirectly122.9K
- Cecilia JonesChief Financial OfficerDirectly55.0K
- Sarah GheuensChief Medical OfficerDirectly54.6K
- James William BurnsChief Legal OfficerDirectly49.3K
- Tsveta MilanovaChief Commercial OfficerDirectly46.8K
- David ScaddenDirectorDirectly20.4K
- Maykin HoDirectorDirectly19.8K
- Rahul D. BallalDirectorDirectly15.2K
- Cynthia SmithDirectorDirectly15.2K
- Kaye I Foster-CheekDirectorDirectly12.5K
- Jeffrey D CapelloDirectorDirectly10.9K
- Adams Catherine OwenDirectorDirectly10.9K
- Krishnan ViswanadhanChief Corp Dev & StrategyDirectly10.3K
- Jay T. BackstromDirectorDirectly1,447
- Theodore James Washburn Jr.Principal Accounting OfficerDirectly868
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Brian GoffChief Executive Officer | 184.5K | – | Apr 2, 2026 | Form 4 |
| Jacqualyn A FouseDirector | 154.2K | – | Jun 18, 2026 | Form 4 |
| David P SchenkeinDirector | 122.9K | – | Feb 27, 2024 | Form 4 |
| Cecilia JonesChief Financial Officer | 55.0K | – | Apr 2, 2026 | Form 4 |
| Sarah GheuensChief Medical Officer | 54.6K | – | Oct 26, 2026 | Form 4 |
| James William BurnsChief Legal Officer | 49.3K | – | Apr 2, 2026 | Form 4 |
| Tsveta MilanovaChief Commercial Officer | 46.8K | – | Apr 2, 2026 | Form 4 |
| David ScaddenDirector | 20.4K | – | Jun 18, 2026 | Form 4 |
| Maykin HoDirector | 19.8K | – | Jun 18, 2026 | Form 4 |
| Rahul D. BallalDirector | 15.2K | – | Jun 18, 2026 | Form 4 |
| Cynthia SmithDirector | 15.2K | – | Jun 18, 2026 | Form 4 |
| Kaye I Foster-CheekDirector | 12.5K | – | Jun 18, 2026 | Form 4 |
| Jeffrey D CapelloDirector | 10.9K | – | Jun 18, 2026 | Form 4 |
| Adams Catherine OwenDirector | 10.9K | – | Jun 18, 2026 | Form 4 |
| Krishnan ViswanadhanChief Corp Dev & Strategy | 10.3K | – | Apr 2, 2026 | Form 4 |
| Jay T. BackstromDirector | 1,447 | – | Jul 8, 2026 | Form 4 |
| Theodore James Washburn Jr.Principal Accounting Officer | 868 | – | Mar 3, 2026 | Form 4 |
A lower bound: it counts only the 17 officers and directors with a market trade since Nov 22, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- XBIState Street(R) SPDR(R) S&P(R) Biotech ETFWeight in the fund0.69%
- LABUDirexion Daily S&P Biotech Bull 3X SharesWeight in the fund0.41%
- IBBiShares Biotechnology ETFWeight in the fund0.16%
- IWNiShares Russell 2000 Value ETFWeight in the fund0.13%
- IWMiShares Russell 2000 ETFWeight in the fund0.07%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.06%
- VBKVanguard Small-Cap Growth Index FundWeight in the fund0.06%
- SCHASchwab U.S. Small-Cap ETFWeight in the fund0.04%
- DFASDimensional U.S. Small Cap ETFWeight in the fund0.04%
- VBVanguard Small-Cap Index FundWeight in the fund0.03%
23 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 222
- Q4 2025: Managers 238
- Q1 2026: Managers 236
- Q2 2026: Managers 238
Institutional investors by quarter
The fund managers holding AGIO, quarter by quarter, from Q3 2013 to Q2 2025, 48 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 238 managers held 66.11M shares, worth $2.5B. During the quarter 39 opened a position, 37 closed one, 94 added and 62 trimmed.
The largest holders, Q2 2026
- BlackRockIn the quarter+12%
- Farallon Capital ManagementIn the quarter+4.1%
- State StreetIn the quarter+5.0%
- Lynx1 Capital ManagementIn the quarter+31%
- D.E. ShawIn the quarter+16%
- Vanguard Portfolio ManagementIn the quarter+11%
- Vanguard Capital ManagementIn the quarter+1.9%
- Armistice CapitalIn the quarter-12%
- Erste Asset ManagementIn the quarter-20%
- Nomura Asset Management InternationalIn the quarter+41%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| BlackRock | 6.46M | +12% | $240M |
| Farallon Capital Management | 5.92M | +4.1% | $220M |
| State Street | 3.53M | +5.0% | $131M |
| Lynx1 Capital Management | 3.41M | +31% | $127M |
| D.E. Shaw | 3.11M | +16% | $115M |
| Vanguard Portfolio Management | 2.90M | +11% | $108M |
| Vanguard Capital Management | 2.68M | +1.9% | $100M |
| Armistice Capital | 2.40M | -12% | $89M |
| Erste Asset Management | 2.15M | -20% | $82M |
| Nomura Asset Management International | 2.11M | +41% | $78M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Agios Pharmaceuticals's filings show?
Who buys and sells is one part of Agios Pharmaceuticals's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have AGIO's insiders bought or sold?
From Jun 16, 2026 to Oct 28, 2026 Agios Pharmaceuticals's insiders bought 0 and sold $1.4M of shares on the market. 100% of the sales were under set 10b5-1 plans.
Which well-known managers hold AGIO?
7 of the managers we track held the shares on Sep 30, 2026. The largest position was D.E. Shaw's, worth $129M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.